old standards—radiography, computed tomography (CT), and magnetic resonance (MR) imaging. A growing body of clinical research findings continues to establish strong evidence of the benefits of the EOS system with regard to its clinical value, the workflow it proposes, return on investment (ROI) model, and the low dose administered to patients."
Compared to traditional radiography solutions, the competitively priced EOS system offers numerous avenues for revenue growth. The higher number of clinical procedures addressed by the EOS system, involving more clinical subspecialties, further boosts the ROI opportunity for providers, while generating synergies throughout the imaging enterprise.
Entering the U.S. market with a new product and brand name only four years ago, EOS Imaging has admirably and substantially increased its mindshare in the medical imaging community. The market's adoption of the EOS system has continued to gain momentum, with more than 20 installations in the U.S., including some of the most prestigious healthcare institutions. EOS imaging is one of the Deloitte 2013 Technology Fast 50 laureate companies.
"EOS Imaging's growth in the U.S. market is in line with the company's achievements in Europe and numerous early successes and promising near-term prospects in several markets, including Japan, Singapore and China," noted Daher. "This universal acknowledgment of EOS Imaging's technology and product value validates the value the company brings to the fields of radiology and orthopedics, and the broader imaging community."
Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leverage leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases Page: 1 2 3 4 5 6 Related medicine technology :1
. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan2
. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant3
. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan4
. Frost & Sullivan Research Preview: Top 20 Telehealth Markets5
. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan6
. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market7
. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan8
. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market9
. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets10
. Electronic Medical Records Progress from an Enterprise-Centric Solution to a Customer-Specific Application, Finds Frost & Sullivan11
. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market